Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

XOMA Corporation (XOMA - Snapshot Report) reported fourth-quarter 2012 loss of 15 cents per share, narrower than the year-ago loss of 36 cents and the Zacks Consensus Estimate of a loss of 24 cents. Lower operating expenses led to the narrower year-over-year loss.

For the full year 2012, XOMA suffered a loss of 88 cents per share as opposed to a loss of $1.16 incurred in 2011. 2012 loss was also narrower than the Zacks Consensus Loss Estimate of a loss of $1.42 per share.

Revenues in 2012 declined 42% to $33.8 million. The top-line figure was nominally below the Zacks Consensus Estimate of $34 million.

Quarterly Results

Revenues at XOMA declined 24.9% to $7.4 million in the fourth quarter of 2012. The decline was primarily due to lower contract revenues during the quarter. Revenues fell short of the Zacks Consensus Estimate of $8 million.

XOMA records revenue from its license and collaboration arrangements, contract services, product sales and royalties.

Revenues from license and collaborative fees came in at $1.1 million, down 16.1%. Contract and other revenues dropped approximately 29% to $6 million. XOMA reported net product sales of $0.25 million in the reported quarter. Revenues from royalties accounted for the balance.

Operating expenses declined 10% to $19.7 million. Both research and development (R&D) expenses (down 24.6%) and selling, general and administrative (SG&A) expenses (down 5.6%) declined in the reported quarter.

Pipeline Update

XOMA is expecting several data readouts on its late stage candidate, gevokizumab. The company is developing the candidate for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU). Gevokizumab is being studied in three clinical trials, namely, EYEGUARD-A, EYEGUARD-B and EYEGUARD-C.

2013 Projection

XOMA expects cash used in operating activities to be $50 million in 2013 primarily due to costs related to late stage studies of EYEGUARD-A, EYEGUARD-B and EYEGUARD-C.

XOMA, a biotechnology company, currently carries a Zacks Rank #3 (Hold). Other biotech companies like Cytokinetics Inc. (CYTK - Snapshot Report), WuXi PharmaTech (WX - Snapshot Report) and Agenus Inc (AGEN - Snapshot Report) presently look more attractive. Cytokinetics and WuXi Pharma carry a Zacks Rank #1 (Strong Buy), while Agenus carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%